Evidence map›Paper›PMID 39591127›Full record

ArticleVaccines2024

Immunogenicity and Antibody Persistence of the Inactivated Quadrivalent Influenza Vaccine in Pediatric Patients Post-Chemotherapy or Allogeneic Hematopoietic Stem Cell Transplantation Versus Healthy Controls.

Mi Yeon Hur, Kyu Ri Kang, Ye Ji Kim, Yoon Kyung Cho, Jae Wook Lee, Nack-Gyun Chung, Bin Cho, Dae Chul Jeong, Jin Han Kang, Hyun Mi Kang

Abstract read
In one paragraph

Article in Vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mi Yeon HurVaccine Bio Research Institute, College of Medicine, Catholic University of Korea, Seoul 06591, Republic of Korea.
Kyu Ri KangVaccine Bio Research Institute, College of Medicine, Catholic University of Korea, Seoul 06591, Republic of Korea.ORCID 0000-0001-9135-1890
Ye Ji KimVaccine Bio Research Institute, College of Medicine, Catholic University of Korea, Seoul 06591, Republic of Korea.
Yoon Kyung ChoVaccine Bio Research Institute, College of Medicine, Catholic University of Korea, Seoul 06591, Republic of Korea.ORCID 0000-0003-1377-4446
Jae Wook LeeDepartment of Pediatrics, College of Medicine, Catholic University of Korea, Seoul 06591, Republic of Korea.ORCID 0000-0002-0735-0287
Nack-Gyun ChungDepartment of Pediatrics, College of Medicine, Catholic University of Korea, Seoul 06591, Republic of Korea.ORCID 0000-0003-4855-390X
Bin ChoDepartment of Pediatrics, College of Medicine, Catholic University of Korea, Seoul 06591, Republic of Korea.
Dae Chul JeongDepartment of Pediatrics, College of Medicine, Catholic University of Korea, Seoul 06591, Republic of Korea.
Jin Han KangVaccine Bio Research Institute, College of Medicine, Catholic University of Korea, Seoul 06591, Republic of Korea.
Hyun Mi KangVaccine Bio Research Institute, College of Medicine, Catholic University of Korea, Seoul 06591, Republic of Korea.

Funding

Green cross biopharma No grant number
6 · The paper itself

Abstract

Pediatric patients who have undergone hematopoietic stem cell transplantation (HSCT) or chemotherapy are at increased risk for severe influenza complications, necessitating annual vaccination. This study evaluated the immunogenicity and antibody persistence of the 2021-2022 seasonal quadrivalent influenza vaccine in pediatric patients post-HSCT or chemotherapy, compared to healthy controls. A prospective cohort study included 80 pediatric participants divided into three groups: chemotherapy (

Indexed as

chemotherapychildrenhematopoietic stem cell transplantationinfluenzavaccine

Identifiers

PMID39591127
PMCPMC11598254

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.